Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions | springermedicine.com

Springer Medicine

Top

Journal of Cardiovascular Translational Research

Published in:

01-11-2014

Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions

Authors: Karen Briley-Saebo, Calvin Yeang, Joseph L. Witztum, Sotirios Tsimikas

Published in: Journal of Cardiovascular Translational Research | Issue 8/2014

Login to get access

Abstract

Oxidation-specific epitopes (OSE) within developing atherosclerotic lesions are key antigens that drive innate and adaptive immune responses in atherosclerosis, leading to chronic inflammation. Oxidized phospholipids and malondialdehyde-lysine epitopes are well-characterized OSE present in human atherosclerotic lesions, particularly in pathologically defined vulnerable plaques. Using murine and human OSE-specific antibodies as targeting agents, we have developed radionuclide and magnetic resonance based nanoparticles, containing gadolinium, manganese or lipid-coated ultrasmall superparamagnetic iron oxide, to non-invasively image OSE within experimental atherosclerotic lesions. These methods quantitate plaque burden, allow detection of lesion progression and regression, plaque stabilization, and accumulation of OSE within macrophage-rich areas of the artery wall, suggesting they detect the most active lesions. Future studies will focus on using “natural” antibodies, lipopeptides, and mimotopes for imaging applications. These approaches should enhance the clinical translation of this technique to image, monitor, evaluate efficacy of novel therapeutic agents, and guide optimal therapy of high-risk atherosclerotic lesions.

1.

Topol, E. J., & Nissen, S. E. (1995). Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation, 92, 2333–2342.PubMedCrossRef

2.

Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., Parise, H., Templin, B., White, R., Zhang, Z., & Serruys, P. W. (2011). A prospective natural-history study of coronary atherosclerosis. The New England Journal of Medicine, 364, 226–235.PubMedCrossRef

3.

Witztum, J. L., & Lichtman, A. H. (2014). The influence of innate and adaptive immune responses on atherosclerosis. Annual Review of Pathology, 9, 73–102.PubMedCrossRef

4.

Lichtman, A. H., Binder, C. J., Tsimikas, S., & Witztum, J. L. (2013). Adaptive immunity in atherogenesis: new insights and therapeutic approaches. The Journal of Clinical Investigation, 123, 27–36.PubMedCentralPubMedCrossRef

5.

Miller, Y. I., Choi, S. H., Wiesner, P., Fang, L., Harkewicz, R., Hartvigsen, K., Boullier, A., Gonen, A., Diehl, C. J., Que, X., Montano, E., Shaw, P. X., Tsimikas, S., Binder, C. J., & Witztum, J. L. (2011). Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circulation Research, 108, 235–248.PubMedCentralPubMedCrossRef

6.

Tsimikas, S., & Miller, Y. I. (2011). Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Current Pharmaceutical Design, 17, 27–37.PubMedCrossRef

7.

Steinberg, D., & Witztum, J. L. (2010). Oxidized low-density lipoprotein and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 30, 2311–2316.PubMedCrossRef

8.

Navab, M., Ananthramaiah, G. M., Reddy, S. T., Van Lenten, B. J., Ansell, B. J., Fonarow, G. C., Vahabzadeh, K., Hama, S., Hough, G., Kamranpour, N., Berliner, J. A., Lusis, A. J., & Fogelman, A. M. (2004). Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research, 45, 993–1007.PubMedCrossRef

9.

Glass, C. K., & Witztum, J. L. (2001). Atherosclerosis: the road ahead. Cell, 104, 503–516.PubMedCrossRef

10.

Aikawa, M., Sugiyama, S., Hill, C. C., Voglic, S. J., Rabkin, E., Fukumoto, Y., Schoen, F. J., Witztum, J. L., & Libby, P. (2002). Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation, 106, 1390–1396.PubMedCrossRef

11.

Palinski, W., Rosenfeld, M. E., Yla-Herttuala, S., Gurtner, G. C., Socher, S. S., Butler, S. W., Parthasarathy, S., Carew, T. E., Steinberg, D., & Witztum, J. L. (1989). Low density lipoprotein undergoes oxidative modification in vivo. PNAS, 86, 1372–1376.PubMedCentralPubMedCrossRef

12.

Yla-Herttuala, S., Palinski, W., Rosenfeld, M. E., Parthasarathy, S., Carew, T. E., Butler, S., Witztum, J. L., & Steinberg, D. (1989). Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. The Journal of Clinical Investigation, 84, 1086–1095.PubMedCentralPubMedCrossRef

13.

Palinski, W., Yla-Herttuala, S., Rosenfeld, M. E., Butler, S. W., Socher, S. A., Parthasarathy, S., Curtiss, L. K., & Witztum, J. L. (1990). Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis, 10, 325–335.PubMedCrossRef

14.

Palinski, W., Horkko, S., Miller, E., Steinbrecher, U. P., Powell, H. C., Curtiss, L. K., & Witztum, J. L. (1996). Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. The Journal of Clinical Investigation, 98, 800–814.PubMedCentralPubMedCrossRef

15.

Tsimikas, S., Palinski, W., Halpern, S. E., Yeung, D. W., Curtiss, L. K., & Witztum, J. L. (1999). Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. Journal of Nuclear Cardiology, 6, 41–53.PubMedCrossRef

16.

Tsimikas, S., Shortal, B. P., Witztum, J. L., & Palinski, W. (2000). In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 20, 689–697.PubMedCrossRef

17.

Shaw, P. X., Horkko, S., Chang, M. K., Curtiss, L. K., Palinski, W., Silverman, G. J., & Witztum, J. L. (2000). Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. The Journal of Clinical Investigation, 105, 1731–1740.PubMedCentralPubMedCrossRef

18.

Tsimikas, S., Palinski, W., & Witztum, J. L. (2001). Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 95–100.PubMedCrossRef

19.

Shaw, P. X., Horkko, S., Tsimikas, S., Chang, M. K., Palinski, W., Silverman, G. J., Chen, P. P., & Witztum, J. L. (2001). Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 1333–1339.PubMedCrossRef

20.

Torzewski, M., Shaw, P. X., Han, K. R., Shortal, B., Lackner, K. J., Witztum, J. L., Palinski, W., & Tsimikas, S. (2004). Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 2307–2312.PubMedCrossRef

21.

Tsimikas, S., Aikawa, M., Miller, F. J., Jr., Miller, E. R., Torzewski, M., Lentz, S. R., Bergmark, C., Heistad, D. D., Libby, P., & Witztum, J. L. (2007). Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 175–181.PubMedCrossRef

22.

Tsimikas, S., Miyanohara, A., Hartvigsen, K., Merki, E., Shaw, P. X., Chou, M. Y., Pattison, J., Torzewski, M., Sollors, J., Friedmann, T., Lai, N. C., Hammond, H. K., Getz, G. S., Reardon, C. A., Li, A. C., Banka, C. L., & Witztum, J. L. (2011). Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. Journal of the American College of Cardiology, 58, 1715–1727.PubMedCentralPubMedCrossRef

23.

Briley-Saebo, K. C., Cho, Y. S., Shaw, P. X., Ryu, S. K., Mani, V., Dickson, S., Izadmehr, E., Green, S., Fayad, Z. A., & Tsimikas, S. (2011). Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. Journal of the American College of Cardiology, 57, 337–347.PubMedCentralPubMedCrossRef

24.

Fang, L., Green, S. R., Baek, J. S., Lee, S. H., Ellett, F., Deer, E., Lieschke, G. J., Witztum, J. L., Tsimikas, S., & Miller, Y. I. (2011). In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. The Journal of Clinical Investigation, 121, 4861–4869.PubMedCentralPubMedCrossRef

25.

Vucic, E., Dickson, S. D., Calcagno, C., Rudd, J. H. F., Moshier, E., Hayashi, K., Mounessa, J. S., Roytman, M., Moon, M. J., Lin, J., Tsimikas, S., Fisher, E. A., Nicolay, K., Fuster, V., & Fayad, Z. A. (2011). Pioglitazone modulates vascular inflammation in atherosclerotic rabbits: noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC: Cardiovascular Imaging, 4, 1100–1109.PubMedCentralPubMedCrossRef

26.

Briley-Saebo, K. C., Nguyen, T. H., Saeboe, A. M., Cho, Y. S., Ryu, S. K., Volkava, E., Dickson, S., Leibundgut, G., Weisner, P., Green, S., Casanada, F., Miller, Y. I., Shaw, W., Witztum, J. L., Fayad, Z. A., & Tsimikas, S. (2012). In vivo detection of oxidation-specific epitopes in atherosclerotic lesions using biocompatible manganese molecular magnetic imaging probes. Journal of the American College of Cardiology, 59, 616–626.PubMedCentralPubMedCrossRef

27.

van Dijk, R. A., Kolodgie, F., Ravandi, A., Leibundgut, G., Hu, P. P., Prasad, A., Mahmud, E., Dennis, E., Curtiss, L. K., Witztum, J. L., Wasserman, B. A., Otsuka, F., Virmani, R., & Tsimikas, S. (2012). Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. Journal of Lipid Research, 53, 2773–2790.PubMedCentralPubMedCrossRef

28.

Vucic, E., Calcagno, C., Dickson, S. D., Rudd, J. H., Hayashi, K., Bucerius, J., Moshier, E., Mounessa, J. S., Roytman, M., Moon, M. J., Lin, J., Ramachandran, S., Tanimoto, T., Brown, K., Kotsuma, M., Tsimikas, S., Fisher, E. A., Nicolay, K., Fuster, V., & Fayad, Z. A. (2012). Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC: Cardiovascular Imaging, 5, 819–828.PubMedCentralPubMedCrossRef

29.

Purushothaman, K. R., Purushothaman, M., Levy, A. P., Lento, P. A., Evrard, S., Kovacic, J. C., Briley-Saebo, K. C., Tsimikas, S., Witztum, J. L., Krishnan, P., Kini, A., Fayad, Z. A., Fuster, V., Sharma, S. K., & Moreno, P. R. (2012). Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. Journal of the American College of Cardiology, 60, 112–119.PubMedCrossRef

30.

Choi, S. H., Yin, H., Ravandi, A., Armando, A., Dumlao, D., Kim, J., Almazan, F., Taylor, A. M., McNamara, C. A., Tsimikas, S., Dennis, E. A., Witztum, J. L., & Miller, Y. I. (2013). Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. PloS One, 8, e83145.PubMedCentralPubMedCrossRef

31.

Ravandi, A., Leibundgut, G., Hung, M.Y., Patel, M., Hutchins, P.M., Murphy, R.C., Prasad, A., Mahmud, E., Miller, Y.I., Dennis, E., Witztum, J.L., & Tsimikas, S. (2014). Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol (in press).

32.

Bergmark, C., Dewan, A., Orsoni, A., Merki, E., Miller, E. R., Shin, M. J., Binder, C. J., Horkko, S., Krauss, R. M., Chapman, M. J., Witztum, J. L., & Tsimikas, S. (2008). A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. Journal of Lipid Research, 49, 2230–2239.PubMedCrossRef

33.

Leibundgut, G., Scipione, C., Yin, H., Schneider, M., Boffa, M. B., Green, S., Yang, X., Dennis, E. A., Witztum, J. L., Koschinsky, M. L., & Tsimikas, S. (2013). Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). Journal of Lipid Research, 54, 2815–2830.PubMedCentralPubMedCrossRef

34.

Tsimikas, S., & Hall, J. H. (2012). Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. Journal of the American College of Cardiology, 60, 716–721.PubMedCrossRef

35.

Kamstrup, P. R., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2014). Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. Journal of the American College of Cardiology, 63, 470–477.PubMedCrossRef

36.

Thanassoulis, G., Campbell, C. Y., Owens, D. S., Smith, J. G., Smith, A. V., Peloso, G. M., Kerr, K. F., Pechlivanis, S., Budoff, M. J., Harris, T. B., Malhotra, R., O’Brien, K. D., Kamstrup, P. R., Nordestgaard, B. G., Tybjaerg-Hansen, A., Allison, M. A., Aspelund, T., Criqui, M. H., Heckbert, S. R., Hwang, S. J., Liu, Y., Sjogren, M., van der Pals, J., Kalsch, H., Muhleisen, T. W., Nothen, M. M., Cupples, L. A., Caslake, M., Di Angelantonio, E., Danesh, J., Rotter, J. I., Sigurdsson, S., Wong, Q., Erbel, R., Kathiresan, S., Melander, O., Gudnason, V., O’Donnell, C. J., & Post, W. S. (2013). Genetic associations with valvular calcification and aortic stenosis. The New England Journal of Medicine, 368, 503–512.PubMedCentralPubMedCrossRef

37.

Hung, M. Y., Witztum, J. L., & Tsimikas, S. (2014). New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A₂-oxidized phospholipid axis. Journal of the American College of Cardiology, 63, 478–480.PubMedCrossRef

38.

Binder, C. J., Horkko, S., Dewan, A., Chang, M. K., Kieu, E. P., Goodyear, C. S., Shaw, P. X., Palinski, W., Witztum, J. L., & Silverman, G. J. (2003). Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nature Medicine, 9, 736–743.PubMedCrossRef

39.

Lewis, M. J., Malik, T. H., Ehrenstein, M. R., Boyle, J. J., Botto, M., & Haskard, D. O. (2009). Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation, 120, 417–426.PubMedCentralPubMedCrossRef

40.

Kyaw, T., Tay, C., Krishnamurthi, S., Kanellakis, P., Agrotis, A., Tipping, P., Bobik, A., & Toh, B. H. (2011). B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circulation Research, 109, 830–U834.PubMedCrossRef

41.

Karvonen, J., Paivansalo, M., Kesaniemi, Y. A., & Horkko, S. (2003). Immunoglobulin M type of autoantibodies to oxidized low-density lipoprotein has an inverse relation to carotid artery atherosclerosis. Circulation, 108, 2107–2112.PubMedCrossRef

42.

Ravandi, A., Boekholdt, S. M., Mallat, Z., Talmud, P. J., Kastelein, J. J., Wareham, N. J., Miller, E. R., Benessiano, J., Tedgui, A., Witztum, J. L., Khaw, K. T., & Tsimikas, S. (2011). Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research, 52, 1829–1836.PubMedCentralPubMedCrossRef

43.

Tsimikas, S., Willeit, P., Willeit, J., Santer, P., Mayr, M., Xu, Q., Mayr, A., Witztum, J. L., & Kiechl, S. (2012). Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. Journal of the American College of Cardiology, 60, 2218–2229.PubMedCrossRef

44.

Osborn, E. A., & Jaffer, F. A. (2013). The advancing clinical impact of molecular imaging in CVD. JACC. Cardiovascular Imaging, 6, 1327–1341.PubMedCrossRef

45.

Lindner, J., & Sinusas, A. (2013). Molecular imaging in cardiovascular disease: which methods, which diseases? Journal of Nuclear Cardiology, 20, 990–1001.PubMedCentralPubMedCrossRef

46.

Jaffer, F.A., & Verjans, J.W. (2013). Molecular imaging of atherosclerosis: clinical state-of-the-art. Heart, 100, (18):1469–77.

47.

Quillard, T., & Libby, P. (2012). Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circulation Research, 111, 231–244.PubMedCentralPubMedCrossRef

48.

Hansson, G. K., & Hermansson, A. (2011). The immune system in atherosclerosis. Nature Immunology, 12, 204–212.PubMedCrossRef

49.

Libby, P., Lichtman, A. H., & Hansson, G. K. (2013). Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity, 38, 1092–1104.PubMedCentralPubMedCrossRef

50.

Greenberg, M. E., Li, X. M., Gugiu, B. G., Gu, X., Qin, J., Salomon, R. G., & Hazen, S. L. (2008). The lipid whisker model of the structure of oxidized cell membranes. The Journal of Biological Chemistry, 283, 2385–2396.PubMedCrossRef

51.

Berliner, J. A., Leitinger, N., & Tsimikas, S. (2009). The role of oxidized phospholipids in atherosclerosis. Journal of Lipid Research, 50(Suppl), S207–S212.PubMedCentralPubMed

52.

Bochkov, V. N., Oskolkova, O. V., Birukov, K. G., Levonen, A. L., Binder, C. J., & Stockl, J. (2010). Generation and biological activities of oxidized phospholipids. Antioxidants & Redox Signaling, 12, 1009–1059.CrossRef

53.

Seimon, T. A., Nadolski, M. J., Liao, X., Magallon, J., Nguyen, M., Feric, N. T., Koschinsky, M. L., Harkewicz, R., Witztum, J. L., Tsimikas, S., Golenbock, D., Moore, K. J., & Tabas, I. (2010). Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metabolism, 12, 467–482.PubMedCentralPubMedCrossRef

54.

Piotrowski, J. J., Shah, S., & Alexander, J. J. (1996). Mature human atherosclerotic plaque contains peroxidized phosphatidylcholine as a major lipid peroxide. Life Sciences, 58, 735–740.PubMedCrossRef

55.

Holvoet, P., Collen, D., & van de Werf, F. (1999). Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA, 281, 1718–1721.PubMedCrossRef

56.

Ehara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., Tsukamoto, Y., Yoshiyama, M., Takeuchi, K., Yoshikawa, J., & Becker, A. E. (2001). Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation, 103, 1955–1960.PubMedCrossRef

57.

Tsimikas, S., Bergmark, C., Beyer, R. W., Patel, R., Pattison, J., Miller, E., Juliano, J., & Witztum, J. L. (2003). Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. Journal of the American College of Cardiology, 41, 360–370.PubMedCrossRef

58.

Palinski, W., Ord, V. A., Plump, A. S., Breslow, J. L., Steinberg, D., & Witztum, J. L. (1994). ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arteriosclerosis and Thrombosis, 14, 605–616.PubMedCrossRef

59.

Palinski, W., Tangirala, R. K., Miller, E., Young, S. G., & Witztum, J. L. (1995). Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 1569–1576.PubMedCrossRef

60.

Weismann, D., Hartvigsen, K., Lauer, N., Bennett, K. L., Scholl, H. P., Charbel Issa, P., Cano, M., Brandstatter, H., Tsimikas, S., Skerka, C., Superti-Furga, G., Handa, J. T., Zipfel, P. F., Witztum, J. L., & Binder, C. J. (2011). Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature, 478, 76–81.PubMedCrossRef

61.

Chang, M. K., Binder, C. J., Torzewski, M., & Witztum, J. L. (2002). C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. PNAS, 99, 13043–13048.PubMedCentralPubMedCrossRef

62.

Chou, M. Y., Fogelstrand, L., Hartvigsen, K., Hansen, L. F., Woelkers, D., Shaw, P. X., Choi, J., Perkmann, T., Backhed, F., Miller, Y. I., Horkko, S., Corr, M., Witztum, J. L., & Binder, C. J. (2009). Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. The Journal of Clinical Research, 119, 1335–1349.

63.

Chang, M. K., Binder, C. J., Miller, Y. I., Subbanagounder, G., Silverman, G. J., Berliner, J. A., & Witztum, J. L. (2004). Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. The Journal of Experimental Medicine, 200, 1359–1370.PubMedCentralPubMedCrossRef

64.

Moore, K. J., & Tabas, I. (2011). Macrophages in the pathogenesis of atherosclerosis. Cell, 145, 341–355.PubMedCentralPubMedCrossRef

65.

Yla-Herttuala, S., Palinski, W., Butler, S. W., Picard, S., Steinberg, D., & Witztum, J. L. (1994). Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arteriosclerosis and Thrombosis, 14, 32–40.PubMedCrossRef

66.

Rosenfeld, M. E., Palinski, W., Yla-Herttuala, S., Butler, S., & Witztum, J. L. (1990). Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis, 10, 336–349.PubMedCrossRef

67.

Yla-Herttuala, S., Palinski, W., Rosenfeld, M. E., Steinberg, D., & Witztum, J. L. (1990). Lipoproteins in normal and atherosclerotic aorta. European History Journal, 11(Suppl E), 88–99.

68.

Horkko, S., Bird, D. A., Miller, E., Itabe, H., Leitinger, N., Subbanagounder, G., Berliner, J. A., Friedman, P., Dennis, E. A., Curtiss, L. K., Palinski, W., & Witztum, J. L. (1999). Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. The Journal of Clinical Investigation, 103, 117–128.PubMedCentralPubMedCrossRef

69.

Leibundgut, G., Witztum, J. L., & Tsimikas, S. (2013). Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis. Current Opinion in Pharmacology, 13, 168–179.PubMedCrossRef

70.

Miller, Y. I., & Tsimikas, S. (2013). Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Current Opinion in Lipidology, 24, 426–437.PubMedCentralPubMed

71.

Taleb, A., Witztum, J. L., & Tsimikas, S. (2011). Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Medecine, 5, 673–694.CrossRef

72.

Tsimikas, S., Lau, H. K., Han, K. R., Shortal, B., Miller, E. R., Segev, A., Curtiss, L. K., Witztum, J. L., & Strauss, B. H. (2004). Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation, 109, 3164–3170.PubMedCrossRef

73.

Tsimikas, S., Kiechl, S., Willeit, J., Mayr, M., Miller, E. R., Kronenberg, F., Xu, Q., Bergmark, C., Weger, S., Oberhollenzer, F., & Witztum, J. L. (2006). Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. Journal of the American College of Cardiology, 47, 2219–2228.PubMedCrossRef

74.

Tsimikas, S., Brilakis, E. S., Miller, E. R., McConnell, J. P., Lennon, R. J., Kornman, K. S., Witztum, J. L., & Berger, P. B. (2005). Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. The New England Journal of Medicine, 353, 46–57.PubMedCrossRef

75.

Kiechl, S., Willeit, J., Mayr, M., Viehweider, B., Oberhollenzer, M., Kronenberg, F., Wiedermann, C. J., Oberthaler, S., Xu, Q., Witztum, J. L., & Tsimikas, S. (2007). Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, 1788–1795.PubMedCrossRef

76.

Tsimikas, S., Mallat, Z., Talmud, P. J., Kastelein, J. J., Wareham, N. J., Sandhu, M. S., Miller, E. R., Benessiano, J., Tedgui, A., Witztum, J. L., Khaw, K. T., & Boekholdt, S. M. (2010). Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. Journal of the American College of Cardiology, 56, 946–955.PubMedCrossRef

77.

Briley-Saebo, K. C., Shaw, P. X., Mulder, W. J., Choi, S. H., Vucic, E., Aguinaldo, J. G., Witztum, J. L., Fuster, V., Tsimikas, S., & Fayad, Z. A. (2008). Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation, 117, 3206–3215.PubMedCrossRef

78.

Friedman, P., Horkko, S., Steinberg, D., Witztum, J. L., & Dennis, E. A. (2002). Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. The Journal of Biological Chemistry, 277, 7010–7020.PubMedCrossRef

79.

Amir, S., Hartvigsen, K., Gonen, A., Leibundgut, G., Que, X., Jensen-Jarolim, E., Wagner, O., Tsimikas, S., Witztum, J. L., & Binder, C. J. (2012). Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. Journal of Lipid Research, 53, 1316–1326.PubMedCentralPubMedCrossRef

80.

Crisby, M., Nordin-Fredriksson, G., Shah, P. K., Yano, J., Zhu, J., & Nilsson, J. (2001). Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 103, 926–933.PubMedCrossRef

81.

Mintz, G. S., Pichard, A. D., Popma, J. J., Kent, K. M., Satler, L. F., Bucher, T. A., & Leon, M. B. (1997). Determinants and correlates of target lesion calcium in coronary artery disease: a clinical, angiographic and intravascular ultrasound study. Journal of the American College of Cardiology, 29, 268–274.PubMedCrossRef

82.

Briley-Saebo, K. C., Geninatti-Crich, S., Cormode, D. P., Barazza, A., Mulder, W. J., Chen, W., Giovenzana, G. B., Fisher, E. A., Aime, S., & Fayad, Z. A. (2009). High-relaxivity gadolinium-modified high-density lipoproteins as magnetic resonance imaging contrast agents. The Journal of Physical Chemistry. B, 113, 6283–6289.PubMedCentralPubMedCrossRef

83.

Nguyen, T. H., Bryant, H., Shapsa, A., Street, H., Mani, V., Fayad, Z. A., Frank, J. A., Tsimikas, S., & Briley-Saebo, K. C. (2014). Manganese G8 dendrimers targeted to oxidation-specific epitopes: In vivo MR imaging of atherosclerosis. J Magn Reson Imaging. doi:10.1002/jmri.24606.

84.

Turner, W. W., Hartvigsen, K., Boullier, A., Montano, E. N., Witztum, J. L., & Vannieuwenhze, M. S. (2012). Design and synthesis of a stable oxidized phospholipid mimic with specific binding recognition for macrophage scavenger receptors. Journal of Medicinal Chemistry, 55, 8178–8182.PubMedCentralPubMedCrossRef

85.

Briley-Saebo, K. C., Johansson, L. O., Hustvedt, S. O., Haldorsen, A. G., Bjornerud, A., Fayad, Z. A., & Ahlstrom, H. K. (2006). Clearance of iron oxide particles in rat liver: effect of hydrated particle size and coating material on liver metabolism. Investigative Radiology, 41, 560–571.PubMedCrossRef

Title: Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions
Authors: Karen Briley-Saebo
Calvin Yeang
Joseph L. Witztum
Sotirios Tsimikas
Publication date: 01-11-2014
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 8/2014
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-014-9590-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties